Gillian Corbett

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 612 citations · Full text

Medicine, Hematology, Pharmacology +10

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Jeff P. Sharman, Versha Banerji, Laura Fogliatto et al. · Blood · 2019 · 61 citations

Medicine, Oncology, Pharmacology +13

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations

Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman et al. · Journal of Clinical Oncology · 2024 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Sodium valproate in combination with ganciclovir induces lysis of EBV‐infected lymphoma cells without impairing EBV‐specific T‐cell immunity

Kimberley Jones, Jamison L. Nourse, Gillian Corbett et al. · International Journal of Laboratory Hematology · 2009 · 29 citations

Medicine, Oncology, Pharmacology +15

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

Hang Quach, Liam Fernyhough, Ross Henderson et al. · British Journal of Haematology · 2017 · 25 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14